These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34380879)

  • 21. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
    Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies.
    Bigi A; Cascella R; Cecchi C
    Neural Regen Res; 2023 Nov; 18(11):2332-2342. PubMed ID: 37282450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ZPD-2, a Small Compound That Inhibits α-Synuclein Amyloid Aggregation and Its Seeded Polymerization.
    Peña-Díaz S; Pujols J; Conde-Giménez M; Čarija A; Dalfo E; García J; Navarro S; Pinheiro F; Santos J; Salvatella X; Sancho J; Ventura S
    Front Mol Neurosci; 2019; 12():306. PubMed ID: 31920537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
    van Rooijen BD; Claessens MM; Subramaniam V
    Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multistep Inhibition of α-Synuclein Aggregation and Toxicity in Vitro and in Vivo by Trodusquemine.
    Perni M; Flagmeier P; Limbocker R; Cascella R; Aprile FA; Galvagnion C; Heller GT; Meisl G; Chen SW; Kumita JR; Challa PK; Kirkegaard JB; Cohen SIA; Mannini B; Barbut D; Nollen EAA; Cecchi C; Cremades N; Knowles TPJ; Chiti F; Zasloff M; Vendruscolo M; Dobson CM
    ACS Chem Biol; 2018 Aug; 13(8):2308-2319. PubMed ID: 29953201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.
    Uversky VN; Li J; Souillac P; Millett IS; Doniach S; Jakes R; Goedert M; Fink AL
    J Biol Chem; 2002 Apr; 277(14):11970-8. PubMed ID: 11812782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
    Foguel D; Suarez MC; Ferrão-Gonzales AD; Porto TC; Palmieri L; Einsiedler CM; Andrade LR; Lashuel HA; Lansbury PT; Kelly JW; Silva JL
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9831-6. PubMed ID: 12900507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.
    Luk KC; Kehm V; Carroll J; Zhang B; O'Brien P; Trojanowski JQ; Lee VM
    Science; 2012 Nov; 338(6109):949-53. PubMed ID: 23161999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Convergence of Dopamine and α-Synuclein: Implications for Parkinson's Disease.
    Mor DE; Ischiropoulos H
    J Exp Neurosci; 2018; 12():1179069518761360. PubMed ID: 29559809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice.
    Karampetsou M; Ardah MT; Semitekolou M; Polissidis A; Samiotaki M; Kalomoiri M; Majbour N; Xanthou G; El-Agnaf OMA; Vekrellis K
    Sci Rep; 2017 Nov; 7(1):16533. PubMed ID: 29184069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Propagation of pathological α-synuclein in marmoset brain.
    Shimozawa A; Ono M; Takahara D; Tarutani A; Imura S; Masuda-Suzukake M; Higuchi M; Yanai K; Hisanaga SI; Hasegawa M
    Acta Neuropathol Commun; 2017 Feb; 5(1):12. PubMed ID: 28148299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
    Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
    J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computational insights into the role of α-strand/sheet in aggregation of α-synuclein.
    Balupuri A; Choi KE; Kang NS
    Sci Rep; 2019 Jan; 9(1):59. PubMed ID: 30635607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
    Mandel S; Maor G; Youdim MB
    J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.
    Sorrentino ZA; Vijayaraghavan N; Gorion KM; Riffe CJ; Strang KH; Caldwell J; Giasson BI
    J Biol Chem; 2018 Dec; 293(49):18914-18932. PubMed ID: 30327435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity.
    Ardah MT; Paleologou KE; Lv G; Abul Khair SB; Kazim AS; Minhas ST; Al-Tel TH; Al-Hayani AA; Haque ME; Eliezer D; El-Agnaf OM
    Front Aging Neurosci; 2014; 6():197. PubMed ID: 25140150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.